German chemical and pharmaceutical company Bayer AG (BAYN.XE) Wednesday said the U.K.'s regulator has confirmed its recommendation, allowing Xarelto to be used to treat blood clots. MAIN FACTS: -The ruling confirms draft guidance by the National Institute for Health and Clinical Excellence, known as NICE, at end-May. -Xarelto can now be used for the treatment of deep vein thrombosis and pulmonary embolism by the U.K.'s National Health Service. -"The NICE endorsement of Xarelto is a significant step forward in the evolution of deep vein thrombosis treatment," Dr. Kemal Malik, head of global development at Bayer HealthCare, said.
